https://platum.kr/archives/186160
Bioventure company RudaCure has aseguró a Serie A inversión of KRW 6 billion.
RudaCure is primarily developing enfermedad de ojo seco and tratamiento del dolor crónicos. The Serie A round included Hanlim Pharmaceutical, Y&Archer Co., Ltd., and CKD Venture Capital as participating inversores.
The inversores stated that they decided to invest after highly evaluating the comercialización potential of RudaCure's tratamiento de la enfermedad de ojo seco 'RCI001,' recognizing its faster secreción lagrimal eficacia, daño corneal recovery capability, and superior instillation compliance and seguridad compared to commercially available competing drugs.
The tratamiento de la enfermedad de ojo seco mercado ha sido growing steadily due to the recent advancement of digital tecnología and the widespread adoption of vision correction procedures. RudaCure's 'RCI001' achieves rapid drug onset while significantly reducing efectos secundarios such as elevated presión intraocular.
